Story perspectives

Retinitis Pigmentosa Market to Surge by 2034

10/15/2025

29 6

Summary

Story summary

The Retinitis Pigmentosa market is projected to grow by 2034 due to increasing prevalence and awareness.
The market was valued at USD 500 million in 2023, with emerging therapies expected to drive growth across the US, EU5, and Japan.
Key companies include SparingVision SAS, ProQR Therapeutics NV, and Viridian Therapeutics Inc.
Nanoscope Therapeutics is advancing gene therapy aimed at treating Retinitis Pigmentosa.
Ocugen's OCU400 shows promise in clinical trials.

1 of 1

Story summary

The Retinitis Pigmentosa market is projected to grow by 2034 due to increasing prevalence and awareness.
The market was valued at USD 500 million in 2023, with emerging therapies expected to drive growth across the US, EU5, and Japan.
Key companies include SparingVision SAS, ProQR Therapeutics NV, and Viridian Therapeutics Inc.
Nanoscope Therapeutics is advancing gene therapy aimed at treating Retinitis Pigmentosa.
Ocugen's OCU400 shows promise in clinical trials.